Halozyme appoints Jim Daly to board of directors

Bitget2026/09/30 20:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Halozyme appointed James “Jim” Daly to its board of directors.
Daly was Incyte’s executive vice president and chief commercial officer from 2012 to 2015.
He previously spent a decade at Amgen, most recently as senior vice president for North America commercial operations, global marketing, commercial development.
Earlier, Daly spent more than 16 years at Glaxo Wellcome/GlaxoSmithKline, including senior vice president and general manager of the U.S. respiratory business.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA59857) on September 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Goldman Sachs strategists have lowered their 12-month target for South Korea's KOSPI Index from 12,000 points to 9,000 points, representing a 25% decrease. Earlier this year, Goldman had raised the target multiple times. The latest downgrade is due to mounting concerns in the market over artificial intelligence (AI) trading.

智通财经•2026/10/25 10:51